WCCT Global Announces CEO Dr. Kenneth Kim as Co-Author in Noteworthy Paediatric Allergy Clinical Trial

May 1, 2014

COSTA MESA, Calif., May 1, 2014 /PRNewswire-iReach/ — Contract research organization WCCT Global announced today that Dr. Kenneth Kim, the CEO of WCCT Global, was the co-author and co-investigator of one of the highest patient enrolling clinical trial sites in the recently published clintrials.gov article. The article, “Effect of Intranasal Triamcinolone Acetonide on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children with Allergic Rhinitis” was published on the PubMed website.

(Photo: http://photos.prnewswire.com/prnh/20140501/83160 )

The 6-week, multi-center study that is detailed in PubMed was designed to investigate the effects of the intranasal corticosteroid on basal HPA axis function in children from 2 to 12 years old at the highest labelled dose. It was concluded that Nasacort AQ HPA Axis effects were the same as the placebo treatment. The results of this trial together with other safety and efficacy data were used by the FDA in their decision to allow over-the-counter sale of the medication. Full details of the clinical trial can be found by going to www.clinicaltrials.gov and entering the trial number NCT01154153.

Dr. Kim has an extensive clinical research background which began when he obtained his summa cum laude graduate status from Harvard College and obtained an MD from Harvard Medical School.

Following this, Dr. Kim began a fellowship at the MIT Sloan School of Management and completed training in internal medicine and allergy/immunology training at UCLA. Dr. Kim is CEO at WCCT Global LLC and has also worked as a medical monitor, consultant, and lead Investigator on more than 500 clinical trials.

WCCT Global has been considered an industry leader for Contract Clinical Research in multiple therapeutic areas including asthma and respiratory clinical research.

More About WCCT Global:

WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, recruitment services, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccine research.

Request more information about WCCT Global by clicking HERE.

Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


Source: PR Newswire

comments powered by Disqus